...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Progress in Artificial Intelligence >The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation
【24h】

The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation

机译：血小板生成素受体激动剂Eltompopag通过铁螯合抑制人巨细胞病毒复制

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs. These effects were ascribed to the effects of eltrombopag on megakaryocytes. Here, we tested whether eltrombopag may also exert direct antiviral effects. Therapeutic eltrombopag concentrations inhibited HCMV replication in human fibroblasts and adult mesenchymal stem cells infected with six different virus strains and drug-resistant clinical isolates. Eltrombopag also synergistically increased the anti-HCMV activity of the mainstay drug ganciclovir. Time-of-addition experiments suggested that eltrombopag interfered with HCMV replication after virus entry. Eltrombopag was effective in thrombopoietin receptor-negative cells, and the addition of Fe3+ prevented the anti-HCMV effects, indicating that it inhibits HCMV replication via iron chelation. This may be of particular interest for the treatment of cytopenias after hematopoietic stem cell transplantation, as HCMV reactivation is a major reason for transplantation failure. Since therapeutic eltrombopag concentrations are effective against drug-resistant viruses, and synergistically increase the effects of ganciclovir, eltrombopag is also a drug-repurposing candidate for the treatment of therapy-refractory HCMV disease.
机译：血小板生成素受体激动剂Eltompopag以免疫调节和抗病毒药物成功地针对人巨细胞病毒（HCMV）的血小板减少症状。这些效应归因于Eltompagag对巨核细胞的影响。在这里，我们测试了Eltompopag是否也可能产生直接的抗病毒效果。治疗性的Eltompag浓度抑制人成纤维细胞中的HCMV复制和用六种不同病毒菌株和耐药临床分离株感染的成人间充质干细胞。 Eltompopag还协同增加了Mainstay药物Ganciclovir的抗HCMV活性。添加时间的实验表明，在病毒进入后的Eltrombopag干扰了HCMV复制。 Eltombopag在血小板生成素受体阴性细胞中是有效的，并且添加Fe3 +阻止抗HCMV效应，表明它抑制了通过铁螯合的HCMV复制。对于造血干细胞移植后，对造血干细胞移植后的细胞分开，这可能特别感兴趣，因为HCMV再激活是移植衰竭的主要原因。由于治疗性的Eltompag浓度是有效的抗耐药病毒，并且协同增加了Ganciclovir的效果，Eltombopag也是治疗难治性HCMV疾病的药物重新淘点候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号